Vanda Pharmaceuticals Inc.
Treatment of circadian rhythm disorders
Last updated:
Abstract:
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Status:
Grant
Type:
Utility
Filling date:
4 Jan 2019
Issue date:
17 Aug 2021